This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:Labopharm's novel trazadone gets writeup in CNS 2009-11-11 04:48 ET - News Release Mr. Mark D'Souza reports LABOPHARM'S NOVEL TRAZODONE FORMULATION SUBJECT OF PUBLICATION IN PEER-REVIEWED MEDICAL JOURNAL
An article has been published in the international journal of neuropsychiatric medicine, CNS Spectrums October, 2009, issue, citing the potential benefit of Labopharm Inc.'s novel trazodone formulation, which contains Contramid. Labopharm's Contramid is the clinically validated proprietary technology that controls the release of active substances from oral medications to optimize drug delivery.
The article is authored by Dr. Stephen Stahl, adjunct professor of psychiatry, University of California, San Diego School of Medicine, as part of a series entitled, "Trends in psychopharmacology, the mechanism of action of trazodone: a multifunctional drug.
"Although trazodone has traditionally been used as a low-dose hypnotic, a new controlled-release formulation that has the potential to improve the tolerability of high doses may provide an opportunity to revisit this multifunctional drug as an antidepressant as well," writes Dr. Stahl in the article's abstract.
The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. |
Top
Print this Page